- Patients with DNA Damage Response (DDR) defects or Mismatched Repair (MMR) deficiency putative biomarker-positive advanced solid tumors of the following histologies: i) castration-resistant prostate cancer (CRPC); ii) lung cancer, including adenocarcinoma, squamous carcinoma, or small cell lung cancer (SCLC); iii) colorectal cancer (CRC) and iv) gynecological tumors (ovarian cancer, endometrial cancer, or cervical cancer).